CAR T-Cell Therapy Active in High-Risk, Refractory CLL – OncLive
OncLive |
CAR T-Cell Therapy Active in High-Risk, Refractory CLL
OncLive “In high-risk CLL patients, CD19 CAR T cells of defined composition can be administered with an acceptable early toxicity profile,” said Cameron Turtle, MBBS, PhD, an attending physician at the Fred Hutchinson Bone Marrow Transplant Program and … |
